Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Paracetamol experimental · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| 3 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Paracetamol (acetaminophen) solution experimental | DRUG | 1 gm IV |
| paracetamol (acetaminophen) solution commercial | DRUG | 1 gm IV |
| placebo | DRUG | equivalent volume IV 0.9% sodium chloride (equivalent volume) |
Inclusion Criteria: * ASA I or II and scheduled for elective surgical extraction of 1 or more impacted mandibular 3rd molars, at least 1 of which must be a fully or partially impacted mandibular 3rd molar requiring mandibular bone removal. * Moderate or severe pain within 4 hours after the completi...
Paracetamol experimental is an investigational small molecule being studied for the treatment of postoperative pain. It is currently in Phase 3 clinical development and has been evaluated in a completed trial for post-surgical dental pain.
Paracetamol experimental is being developed by Baxter International Inc., a company traded on the New York Stock Exchange under the ticker symbol BAX.
Paracetamol experimental is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 3 trial has been completed.
Paracetamol experimental has one completed Phase 3 trial, NCT00406679, titled 'Analgesic Efficacy, Safety and Tolerability of Two Paracetamol-containing Solutions in Post-Surgical Dental Pain'. The trial enrolled 135 participants in the United Kingdom.
Paracetamol experimental is a formulation of paracetamol being investigated for postoperative pain. It is distinct from standard paracetamol products in that it is being studied in a clinical trial setting for a specific indication.